{"filing":{"accession_number":"0001628280-26-046936","cik":"0002007191","ticker":"TLPPF","company_name":"Telix Pharmaceuticals Ltd","form":"6-K","filing_date":"2026-07-02","report_date":null,"primary_document":"telix-6kforprostactglobalp.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2007191/000162828026046936/telix-6kforprostactglobalp.htm"},"events":[{"id":15883,"run_id":14164,"accession_number":"0001628280-26-046936","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"This announcement discloses a successful Type B meeting with the FDA regarding the ProstACT Global Phase 3 trial of TLX591-Tx, with FDA alignment on advancement into Part 2 in the United States. The disclosure covers regulatory approval of the clinical protocol, statistical framework, and safety data sufficiency to proceed with U.S. enrollment. This is a material operational/regulatory milestone for a clinical-stage therapeutic candidate in a pivotal trial, affecting the company's development timeline and commercial prospects, but does not fit the specific event types (e.g., it is not a discrete M\u0026A activity, earnings release, or executive change).","company_name":"Telix Pharmaceuticals Ltd","ticker":"TLPPF","filing_date":"2026-07-02","form":"6-K","submitted_at":null,"items":[{"id":13800,"accession_number":"0001628280-26-046936","item_number":"EX-99.1","item_title":"a20260702fdaalignmentpro.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This announcement discloses a successful Type B meeting with the FDA regarding the ProstACT Global Phase 3 trial of TLX591-Tx, with FDA alignment on advancement into Part 2 in the United States. The disclosure covers regulatory approval of the clinical protocol, statistical framework, and safety data sufficiency to proceed with U.S. enrollment. This is a material operational/regulatory milestone for a clinical-stage therapeutic candidate in a pivotal trial, affecting the company's development timeline and commercial prospects, but does not fit the specific event types (e.g., it is not a discrete M\u0026A activity, earnings release, or executive change).","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-02T20:28:44.486408+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":13800,"accession_number":"0001628280-26-046936","item_number":"EX-99.1","item_title":"a20260702fdaalignmentpro.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This announcement discloses a successful Type B meeting with the FDA regarding the ProstACT Global Phase 3 trial of TLX591-Tx, with FDA alignment on advancement into Part 2 in the United States. The disclosure covers regulatory approval of the clinical protocol, statistical framework, and safety data sufficiency to proceed with U.S. enrollment. This is a material operational/regulatory milestone for a clinical-stage therapeutic candidate in a pivotal trial, affecting the company's development timeline and commercial prospects, but does not fit the specific event types (e.g., it is not a discrete M\u0026A activity, earnings release, or executive change).","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-02T20:28:44.486408+00:00","company_name":"Telix Pharmaceuticals Ltd","ticker":"TLPPF","filing_date":"2026-07-02"}]}